Shares of Henry Schein (HSIC), a leading distributor of dental and medical products, surged 11.51% in Tuesday's pre-market trading following the company's announcement of robust third-quarter results and an upward revision of its full-year earnings guidance.

The company reported a record third quarter for 2025, with adjusted earnings per share of $1.38, surpassing analysts' expectations of $1.28. Quarterly revenue also beat estimates, coming in at $3.34 billion compared to the projected $3.28 billion. This strong performance was driven by accelerated sales growth across all reportable segments, with significant contributions from Global Technology and Global Specialty Products.

In light of these impressive results, Henry Schein raised its 2025 non-GAAP EPS guidance to a range of $4.88 to $4.96, up from the previous outlook of $4.80 to $4.94. The company also increased its 2025 total sales growth forecast to 3%-4%, up from the previous 2%-4% range. Additionally, Henry Schein announced value creation initiatives expected to deliver over $200 million in operating income improvements over the next few years. The company's board has also approved an amendment to its strategic partnership agreement, allowing KKR to increase its stock ownership up to 19.9%, potentially signaling further confidence in the company's future prospects.